Figure 4.

Cox models (and 95% CIs) of cumulative incidence of mortality for CKD patients (A), major adverse cardiac events (MACE) for CKD disease patients (B), mortality for HF patients (C), and MACE for HF patients (D). Each graph compares 3 patient groups: (1) those who did not receive any RAASi therapy during the follow‐up and patients who spent the majority of their follow‐up on either (2) <50% or (3) ≥50% of the European Society of Cardiology guideline‐recommended dose. RAASi indicates renin–angiotensin–aldosterone system inhibitors.